Rstor1, The King deal has nothing to do with Oxytrex. My question was whether the Oxytrex endpoint change has been given the OK by the FDA? The October press release only said that the change was submitted, and said nothing about whether the FDA has agreed to base their approval on the new lowered endpoints.
Concerning Remoxy, in your previous post you said that the combination of the 15-20% royalty plus having King pay the Durect royalty would equate to PTIE and King effectively splitting the revenues from Remoxy. But even with King paying the Durect royalty, the split is still very onesided - approx 25/75.
The $150 mil in upfronts was great, but I don't like PTIE giving away 75% of future revenues from a blockbuster like Remoxy. Remoxy can be a Bil+ drug, and its chances for approval are very high. PTIE just gave up $750 mil or more/year in revenues, and Remoxy was the one sure thing in their pipeline.
